Novartis is seeking to advance the use of its radiopharmaceutical, Pluvicto, in the treatment of prostate cancer, aiming for its application in earlier stages of the...
Tourmaline Bio has successfully completed a significant acquisition agreement with Novartis valued at $1.4 billion. The deal, finalized after months of negotiations, reflects Novartis’s commitment to...
